摘要
目的探讨血清内源性可溶性终末糖基化产物受体（esRAGE）水平与早期非糖尿病慢性肾脏病（CKD）患者左心室肥厚（LVH）的关系。方法选择2012年12月-2013年7月于新疆医科大学第五附属医院肾病科住院与门诊就诊的CKD 1～3期患者70例为CKD组,并选取同期健康体检者50例为对照组,根据心脏彩超结果计算所得左室质量指数（LVMI）,将患者分为慢性肾脏病伴左室肥厚组（CKD-LVH组）与慢性肾脏病非左室肥厚组（CKD-NLVH组）,采用酶联免疫吸附法测定血清esRAGE水平,分析esRAGE水平与慢性肾衰竭患者左心室肥厚的相关性。结果 CKD组收缩压、LVMI、血糖、血磷、血清esRAGE水平均高于对照组（P〈0.05）,而血红蛋白、肌酐、GFR水平均低于对照组（P〈0.05）。CKD-LVH组esRAGE为（0.70±0.31）ng/mL,明显低于CKDNLVH组的（1.40±0.99）ng/mL（P〈0.05）。CKD组esRAGE水平与左室质量指数（LVMI）呈负相关（r=-0.362,P〈0.05）,Logistic回归分析显示esRAGE与早期CKD患者左心室肥厚具有相关性[OR=0.18,95%CI（0.04～0.82）,P〈0.05]。结论 esRAGE在CKD早期即可增高,其水平与LVMI呈负相关,esRAGE水平的升高可能是CKD患者左心室肥厚的保护性因素。
Objective To research the association of the level of endogenous secretory soluble form of advanced glycation end products receptor（esRAGE） with left ventricular hypertrophy in patients with early chronic kidney disease（CKD）.Methods Between December 2012 and July 2013,70 cases with early chronic kidney disease were divided into 2 groups： patients with left ventricular hypertrophy（CKD-LVH group） and patients without left ventricular hypertrophy（CKD-NLVH group）.Meanwhile,50 healthy subjects were as control group.all these patients were tested the level of esRAGE and creatinine.The cardiac lumen diameters were measured by echocardiography and left ventricular mass index（LVMI） was calculated.Results The level of esRAGE in CKDgroup was significantly higher than that of control（P〈0.05）.Moreover,it in CKD-LVH group was lower than CKD-NLVH group.EsRAGE was related inversely with LVMI（P〈0.05）.Conclusion EsRAGE increased in patients with early chronic kidney disease.Maybe it can partly prevent chronic kidney disease patients from left ventricular hypertrophy.
出处
《新疆医科大学学报》
CAS
2015年第5期594-597,共4页
Journal of Xinjiang Medical University
基金
新疆维吾尔自治区自然科学基金(2014211C125)
关键词
ESRAGE
慢性肾脏病
左心室肥厚
esRAGE
chronic kidney disease
left ventricular hypertrophy
